Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.24875/RIC.21000028 http://scihub22266oqcxt.onion/10.24875/RIC.21000028 34019535!ä!34019535 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Rev+Invest+Clin 2021 ; 73 (3): 190-198 Nephropedia Template TP {{tp|p=34019535|t=2021. METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2 |pdf=|usr=}}{{34019535}} gab.com Text METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2 JO: Rev Invest Clin http://www.kidney.de/pget.php?&tw=1&pmid=34019535 #FOAvip BACKGROUND: There is no pharmacological intervention on the treatment of hypoxemia and respiratory distress in COVID-19 patients. OBJECTIVE: The objective of the study was to study the effect of the reduced form of methylene blue (MB) on the improvement of oxygen saturation (SpO(2)) and respiratory rate (RR). METHODS: In an academic medical center, 80 hospitalized patients with severe COVID-19 were randomly assigned to receive either oral MB along with standard of care (SOC) (MB group, n = 40) or SOC only (SOC group, n=40). The primary outcomes were SpO(2) and RR on the 3(rd) and 5(th) days. The secondary outcomes were hospital stay and mortality within 28 days. RESULTS: In the MB group, a significant improvement in SpO(2) and RR was observed on the 3(rd) day (for both, p < 0.0001) and also the 5(th) day (for both, p < 0.0001). In the SOC group, there was no significant improvement in SpO(2) (p = 0.24) and RR (p = 0.20) on the 3(rd) day, although there was a significant improvement of SpO(2) (p = 0.002) and RR (p = 0.01) on the 5(th) day. In the MB group in comparison to the SOC group, the rate ratio of increased SpO(2) was 13.5 and 2.1 times on the 3(rd) and 5(th) days, respectively. In the MB group compared with the SOC group, the rate ratio of RR improvement was 10.1 and 3.7 times on the 3(rd) and 5(th) days, respectively. The hospital stay was significantly shortened in the MB group (p = 0.004), and the mortality was 12.5% and 22.5% in the MB and SOC groups, respectively. CONCLUSIONS: The addition of MB to the treatment protocols significantly improved SpO(2) and respiratory distress in COVID-19 patients, which resulted in decreased hospital stay and mortality. ClinicalTrials.gov: NCT04370288. Twit Text FOAVip METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2 ????Rev Invest Clin http://www.kidney.de/pget.php?&tw=1&pmid=34019535 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34019535 #FOAvip English Wikipedia <ref>{{Cite pmid|34019535}}</ref> METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2 #MMPMID34019535 Hamidi-Alamdari D; Hafizi-Lotfabadi S; Bagheri-Moghaddam A; Safari H; Mozdourian M; Javidarabshahi Z; Peivandi-Yazdi A; Ali-Zeraati A; Sedaghat A; Poursadegh F; Barazandeh-Ahmadabadi F; Agheli-Rad M; Tavousi SM; Vojouhi S; Amini S; Amini M; Majid-Hosseini S; Tavanaee-Sani A; Ghiabi A; Nabavi-Mahalli S; Morovatdar N; Rajabi O; Koliakos G Rev Invest Clin 2021[]; 73 (3): 190-198 PMID34019535show ga BACKGROUND: There is no pharmacological intervention on the treatment of hypoxemia and respiratory distress in COVID-19 patients. OBJECTIVE: The objective of the study was to study the effect of the reduced form of methylene blue (MB) on the improvement of oxygen saturation (SpO(2)) and respiratory rate (RR). METHODS: In an academic medical center, 80 hospitalized patients with severe COVID-19 were randomly assigned to receive either oral MB along with standard of care (SOC) (MB group, n = 40) or SOC only (SOC group, n=40). The primary outcomes were SpO(2) and RR on the 3(rd) and 5(th) days. The secondary outcomes were hospital stay and mortality within 28 days. RESULTS: In the MB group, a significant improvement in SpO(2) and RR was observed on the 3(rd) day (for both, p < 0.0001) and also the 5(th) day (for both, p < 0.0001). In the SOC group, there was no significant improvement in SpO(2) (p = 0.24) and RR (p = 0.20) on the 3(rd) day, although there was a significant improvement of SpO(2) (p = 0.002) and RR (p = 0.01) on the 5(th) day. In the MB group in comparison to the SOC group, the rate ratio of increased SpO(2) was 13.5 and 2.1 times on the 3(rd) and 5(th) days, respectively. In the MB group compared with the SOC group, the rate ratio of RR improvement was 10.1 and 3.7 times on the 3(rd) and 5(th) days, respectively. The hospital stay was significantly shortened in the MB group (p = 0.004), and the mortality was 12.5% and 22.5% in the MB and SOC groups, respectively. CONCLUSIONS: The addition of MB to the treatment protocols significantly improved SpO(2) and respiratory distress in COVID-19 patients, which resulted in decreased hospital stay and mortality. ClinicalTrials.gov: NCT04370288. |*COVID-19 Drug Treatment[MESH] |Adult[MESH] |Aged[MESH] |Female[MESH] |Hospitalization[MESH] |Humans[MESH] |Male[MESH] |Methylene Blue/*therapeutic use[MESH]METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RAND(epmc).pdf DeepDyve Pubget Overpricing